Daniel Joseph OConnell - 06 Jul 2021 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role: President and CEO, Director
Signature: /s/ Katherine Denby, Attorney-in-Fact
Issuer symbol: ABOS
Transactions as of: 06 Jul 2021
Net transactions value: -$3.55
Form type: 4
Filing time: 08 Jul 2021, 18:16:31 UTC
Previous filing: 30 Jun 2021
Next filing: 02 Dec 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABOS	Common Stock	Conversion of derivative security		+123	+8.7%		1,542	06 Jul 2021	Direct	F1
transaction	ABOS	Common Stock	Exercise of in-the-money or at-the-money derivative security	$156	+35	+2.3%	$4.47	1,577	06 Jul 2021	Direct
transaction	ABOS	Common Stock	Tax liability	$160	-10	-0.63%	$16.00	1,567	06 Jul 2021	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABOS	Series A Preferred Stock	Conversion of derivative security		-123	-100%		0	06 Jul 2021	Common Stock	123		Direct	F1
transaction	ABOS	Warrant (Right to Buy)	Options Exercise	$0	-35	-100%	$0.000000^*	0	06 Jul 2021	Common Stock	35	$4.47	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On July 6, 2021, each share of Series A Convertible Preferred Stock (the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F2	On July 6, 2021, the reporting person exercised a warrant to purchase 35 shares of ABOS common stock for $4.47 a share. The reporting person paid the exercise price on a cashless basis, resulting in ABOS's withholding of 10 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 25 shares.